Rethinking of cytotoxic/immunosuppressive chemotherapy mixing with immune-based therapeutics.

Investors’ Soapbox PM

Cancer therapy may see major shift.

There’s evidence cytotoxic/immunosuppressive chemotherapy can be combined with immune-based therapeutics.